新闻来自Deadline。原文地址:http://deadline.com/2016/06/adam-mckay-jennifer-lawrence-theranos-movie-bad-blood-1201775531/
A total of nine bidders are in the mix thisevening, a day after McKay pitched his vision for the hot-button film he’llwrite and direct, very much in the spirit of last year’s The Big Short — forwhich he and Charles Randolph shared an Adapted Screenplay Oscar. The biddingright now is in the $3 million-$4 million range for his screenplay, for a filmthat will fall in the $40 million-$50 million budget range. As for thecontenders:Universal and Legendary Pictures are the names we are hearing themost right now, along with Fox 2000, Warner Bros, Morgan Creek, STX Entertainment,Cross Creek, Paramount, AG Capital and The Weinstein Company:, with AmazonStudios orbiting as well.
The package includes a book proposal bytwo-time Pulitzer Prize winner John Carreyrou, who has written articles onTheranos for The Wall Street Journal. This one could land tonight, or bytomorrow at the latest. It has all the requisites for the big packages studiosare responding to right now: hot-button subject matter, McKay coming off hisOscar for Big Short and Oscar winner Lawrence, who usually finds herself in theAcademy Awards mix on prestige projects, most recently Joy. Bad Blood certainlyis the hottest picture package since the Max Landis-scripted spec Bright, whichNetflix won with a $90 million commitment with Will Smith and Joel Edgerton starring.
This has been top of buyers’ lists eversince Deadline first revealed that Lawrence and McKay would be teaming on theproject. Almost every major player was looking at this seriously over theweekend, with offers on the table even before McKay was scheduled to give hispresentation starting today. The background materials, watermarked to preventleaks, went out on Friday. The combination of McKay and Lawrence — Hollywood’smost bankable female star — in a provocative and timely project offers thepotential for a movie in the spirit of The Big Short and The Social Network,with both box office and awards-season potential.
This time around the focus will be onSilicon Valley bubbles and how Wall Street falls in love with the potentialbehind a potentially disruptive company, and the complications that can arise.Theranos is the blood-testing startup that Holmes founded in 2003, with claimsit could test blood with only a pinprick instead of the traditional method ofdrawing blood by injection. That potential left Theranos with a $9 billionvaluation as recently as two years ago. The company since has come underinvestigation over claims of inaccurate testing, and Holmes’ own worth — at onepoint valued at $4.5 billion for her 50% stake — has fallen to a fraction ofthat. The last valuation by Forbes placed the company’s net worth at $800million.
Gary Sanchez is producing the film withLawrence and McKay. He is repped by WME and Mosaic; Lawrence is with CAA. WMEhas been leading the charge on the auction.
A total of nine bidders are in the mix thisevening, a day after McKay pitched his vision for the hot-button film he’llwrite and direct, very much in the spirit of last year’s The Big Short — forwhich he and Charles Randolph shared an Adapted Screenplay Oscar. The biddingright now is in the $3 million-$4 million range for his screenplay, for a filmthat will fall in the $40 million-$50 million budget range. As for thecontenders:Universal and Legendary Pictures are the names we are hearing themost right now, along with Fox 2000, Warner Bros, Morgan Creek, STX Entertainment,Cross Creek, Paramount, AG Capital and The Weinstein Company:, with AmazonStudios orbiting as well.
The package includes a book proposal bytwo-time Pulitzer Prize winner John Carreyrou, who has written articles onTheranos for The Wall Street Journal. This one could land tonight, or bytomorrow at the latest. It has all the requisites for the big packages studiosare responding to right now: hot-button subject matter, McKay coming off hisOscar for Big Short and Oscar winner Lawrence, who usually finds herself in theAcademy Awards mix on prestige projects, most recently Joy. Bad Blood certainlyis the hottest picture package since the Max Landis-scripted spec Bright, whichNetflix won with a $90 million commitment with Will Smith and Joel Edgerton starring.
This has been top of buyers’ lists eversince Deadline first revealed that Lawrence and McKay would be teaming on theproject. Almost every major player was looking at this seriously over theweekend, with offers on the table even before McKay was scheduled to give hispresentation starting today. The background materials, watermarked to preventleaks, went out on Friday. The combination of McKay and Lawrence — Hollywood’smost bankable female star — in a provocative and timely project offers thepotential for a movie in the spirit of The Big Short and The Social Network,with both box office and awards-season potential.
This time around the focus will be onSilicon Valley bubbles and how Wall Street falls in love with the potentialbehind a potentially disruptive company, and the complications that can arise.Theranos is the blood-testing startup that Holmes founded in 2003, with claimsit could test blood with only a pinprick instead of the traditional method ofdrawing blood by injection. That potential left Theranos with a $9 billionvaluation as recently as two years ago. The company since has come underinvestigation over claims of inaccurate testing, and Holmes’ own worth — at onepoint valued at $4.5 billion for her 50% stake — has fallen to a fraction ofthat. The last valuation by Forbes placed the company’s net worth at $800million.
Gary Sanchez is producing the film withLawrence and McKay. He is repped by WME and Mosaic; Lawrence is with CAA. WMEhas been leading the charge on the auction.